A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3Â + toxicities in men undergoing chemotherapy for metastatic prostate cancer

Chemotherapy for mCRPC was associated with lower than predicted rates of severe toxicity across all predicted risk groups. Further disease-specific validation studies are warranted.